Navigation Links
Incisive Surgical Announces Breakthrough Peer Review Clinical Study
Date:1/17/2012

MINNEAPOLIS, Jan. 17, 2012 /PRNewswire/ -- Incisive Surgical, Inc. today announced a peer-reviewed publication of a profound clinical study. The study, titled "Skin Closure With Subcuticular Absorbable Staples After Cesarean Section Is Associated With Decreased Analgesic Use," was published online by the Archives of Gynecology & Obstetrics Journal in October 2011. The authors, Drs. Joshua Nitsche (Mayo Clinic College of Medicine, Rochester, MN) and Thomas Howe (District One Hospital, Fairbault, MN), concluded that "our results suggest that the use of subcuticular absorbable staples for skin closure at the time of cesarean section may lead to less in-hospital analgesic use … are associated with less pain immediately post-operatively when pain can be the most difficult to control… [and] would result in a cost savings of approximately $200 per patient even after considering the higher cost of the absorbable staple device." The unique INSORB Absorbable Skin Stapling Technology is a revolutionary new skin closure technology that places an absorbable staple entirely underneath the skin to close surgical incisions. Patients now have a more comfortable, convenient and cosmetic choice for rapid skin closure. This unique device has won several national awards, including the 2006 Wall Street Journal Technology Innovation of the Year Award for medical devices. Incisive Surgical is the only company in the world that offers this technology and has sold over 750,000 INSORB® Absorbable Skin Staplers since the product launch in January 2005.

"The results of this peer-review clinical study are profound," said John L. Shannon, Jr., president and chief executive officer of Incisive Surgical. "The INSORB Staple does not pierce and puncture the outside of the patient's skin like metal skin staples, and this study suggests that the INSORB Skin Closure Technology may lead to higher patient satisfaction with reduced costs."

In addition, the Company announced that the U.S. Patent and Trademark Office (USPTO) issued the Company two additional key patents for its proprietary INSORB® Absorbable Skin Stapling Technology during the fourth quarter of 2011. The allowed claims for these two patents include comprehensive subject matter covering the method and apparatus of the INSORB Skin Closure technology, as well as the design of the absorbable staple. The Company holds nine INSORB Patents – seven in the United States and two in Japan – with two patents pending in Europe.

The INSORB Absorbable Skin Stapler offers the speed of metal skin staplers with the cosmetic results and comfort of absorbable sutures. The INSORB Stapler uses bioabsorbable staples that are placed underneath the skin and dissolve in the body within a matter of months. The staples, which are comprised of the same material as the leading bioabsorbable sutures, break down naturally, thereby eliminating the anxiety, pain, cost and inconvenience of post-operative staple removal.

About Incisive Surgical

Incisive Surgical, Inc. is a privately-held medical device company established to develop innovative cost-effective patient-centric solutions for skin closure. For more information or to request a media kit, contact info@insorb.com or visit www.insorb.com. To learn more about skin closure options and patients' rights, visit www.ihatemetalskinstaples.com.

John L. Shannon Jr.
952-591-2543, ext. 18
shannon@insorb.com

 

 

 

 


'/>"/>
SOURCE Incisive Surgical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Incisive Surgical Issued Notice of Allowance for Key Absorbable Skin Stapler Patent
2. Incisive Surgical Launches New National Patient Advocacy Campaign -- Eliminate Traumatic Metal Skin Staples for Routine Skin Closure
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... TAIPEI, Taiwan , Dec. 5, 2016 /PRNewswire/ ... ropeginterferon alfa-2b showed non-inferiority to hydroxyurea (HU) in Complete Hematologic ... safety and tolerability profile of ropeginterferon alfa-2b versus HU ... the ongoing long-term follow-up trial CONTINUATION-PV to obtain European marketing ... to present this data to the FDA as it seeks ...
(Date:12/4/2016)... -- Sickle cell disease (SCD) is an inherited chronic ... get stuck in veins and block blood flow, which ... leading to death. Each year, approximately 300,000 people around ... them lack access to comprehensive care or effective treatment ... SCD, a pill called hydroxyurea approved more than a ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. ... scholarship funds for area students and operating support to UNCF-member institutions, including Miles ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... announces the launch of its 60-day free trial program for all of the ... make the offer a truly hassle free experience. , FlexiSpot’s unique desktop risers ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to ... Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to ... drug plan (Part D) need to make changes during this period order for their ...
(Date:12/2/2016)... PA (PRWEB) , ... December 02, 2016 , ... With ... struggling through rehabilitation of an injury, patients must find the one that works for ... his pain, he created a machine that worked and decided to share it with ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a ... in the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. ... their education, experience, and professional associations. , One the most frequently honored ...
Breaking Medicine News(10 mins):